Guide To The Turbulent Times At The Top of Teva
Executive Summary
While the rumor mill continues to turn over Pascal Soriot jumping ship from AstraZeneca to Teva, the experience of previous CEOs shows that the chair at the head of the Israeli drug maker’s table is a very hot seat indeed.
You may also be interested in...
Will Soriot Ditch AstraZeneca In Favor Of Teva… And A $20m Bonus?
Pascal Soriot is reportedly about to abandon his top role at UK big pharma AstraZeneca to join Israel's generics giant Teva – a switch that could see him receive a $20m signing bonus, if the rumors are to be believed.
Verona Transformed After Phase III Victory For COPD Therapy
The UK firm's ensifentrine has exceeded analyst expectations by cutting the rate of moderate to severe COPD exacerbations by 42% over 24 weeks.
Galapagos Keeps Analysts Guessing About Future Plans
Analysts are scratching their heads over what direction the Belgian biotech will take in the coming months and years, with all eyes on an R&D day in October.